Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer

被引:0
|
作者
Antoni Llueca
María Teresa Climent
Javier Escrig
Paula Carrasco
Anna Serra
机构
[1] University General Hospital of Castellon,Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS)
[2] University Jaume I (UJI),Department of Medicine
[3] Consorci Hospitalari Provincial de Castello,Department of Oncology
[4] Consorci Hospitalari Provincial de Castello,Department of Radiotherapy
[5] Consorci Hospitalari Provincial de Castello,Department of Plastic Surgery
[6] Consorci Hospitalari Provincial de Castello,Department of Surgery
[7] La Plana University Hospital,Department of Obsterics and Gynecology
[8] La Plana University Hospital,Department of Surgery
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The standard treatment for advanced ovarian cancer (AOC) is cytoreduction surgery and adjuvant chemotherapy. Tumor volume after surgery is a major prognostic factor for these patients. The ability to perform complete cytoreduction depends on the extent of disease and the skills of the surgical team. Several predictive models have been proposed to evaluate the possibility of performing complete cytoreductive surgery (CCS). External validation of the prognostic value of three predictive models (Fagotti index and the R3 and R4 models) for predicting suboptimal cytoreductive surgery (SCS) in AOC was performed in this study. The scores of the 3 models were evaluated in one hundred and three consecutive patients diagnosed with AOC treated in a tertiary hospital were evaluated. Clinicopathological features were collected prospectively and analyzed retrospectively. The performance of the three models was evaluated, and calibration and discrimination were analyzed. The calibration of the Fagotti, R3 and R4 models showed odds ratios of obtaining SCSs of 1.5, 2.4 and 2.4, respectively, indicating good calibration. The discrimination of the Fagotti, R3 and R4 models showed an area under the ROC curve of 83%, 70% and 81%, respectively. The negative predictive values of the three models were higher than the positive predictive values for SCS. The three models were able to predict suboptimal cytoreductive surgery for advanced ovarian cancer, but they were more reliable for predicting CCS. The R4 model discriminated better because it includes the laparotomic evaluation of the peritoneal carcinomatosis index.
引用
收藏
相关论文
共 50 条
  • [41] Minimally invasive approach for interval cytoreductive surgery for advanced ovarian cancer
    McNamara, Blair
    Guerra, Rosa Alisa
    Craig, Amaranta D.
    Chen, Lee-may
    Chapman, Jocelyn S.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : E30 - E30
  • [42] Stuuy on the secondary cytoreductive surgery for patients with advanced ovarian epithelial cancer
    ZngRongyuZhngZhiyiTheCncerHospitloftheShnghiMediclUniversity AbstrctObjective TostudyonthesecondarycytoreductivesurgerySCRSforptientswithovrinepithelilcncerOECMethodsLiterturesaboutSCBSforptientswithdvncedOECfromtofoundinMEDLINE
    现代妇产科进展, 1999, (02) : 97 - 100
  • [43] MORBIDITY ASSOCIATED WITH EXTENSIVE CYTOREDUCTIVE SURGERY FOR ADVANCED STAGES OF OVARIAN CANCER
    Gan, C.
    Chiang, P. W.
    Banks, A.
    Gajjar, K.
    Davies, M.
    Williamson, K.
    Nunns, D.
    Mohiuddin, K.
    Bharathan, B.
    Irving, G.
    Navarro, A.
    Gomez, D.
    Abu, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 686 - 687
  • [44] Bowel resection at time of interval cytoreductive surgery for advanced ovarian cancer
    McNamara, Blair
    Guerra, Rosa Alisa
    Craig, Amaranta D.
    Chen, Lee-may
    Chapman, Jocelyn S.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : E29 - E30
  • [45] Utilization of Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer
    Bercow, Alexandra
    Stewart, Taylor
    Bregar, Amy J.
    Gockley, Allison
    Mazina, Varvara
    Rauh-Hain, J. Alejandro
    Melamed, Alexander
    JAMA NETWORK OPEN, 2024, 7 (10)
  • [46] Hypoalbuminemia alone is not a contraindication to primary cytoreductive surgery in advanced ovarian cancer
    Finch, Lindsey
    Dagher, Christian
    Finlan, Michael
    Kahn, Ryan
    Yeoshoua, Effi
    Broach, Vance
    Roche, Kara Long
    Gardner, Ginger
    Sonoda, Yukio
    Abu-Rustum, Nadeem
    Chi, Dennis
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S258 - S259
  • [47] Splenectomy in cytoreductive surgery for advanced ovarian cancer and subsequent intraperitoneal chemotherapy
    Pant, A.
    Santillan, A.
    McCormick, C. C.
    Diaz-Montes, T.
    Giuntoli, R. L.
    Bristow, R. E.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S151 - S152
  • [48] EXTENSIVE PRIMARY CYTOREDUCTIVE SURGERY FOR ADVANCED EPITHELIAL OVARIAN-CANCER
    GUIDOZZI, F
    BALL, JHS
    GYNECOLOGIC ONCOLOGY, 1994, 53 (03) : 326 - 330
  • [49] Primary Versus Interval Cytoreductive Surgery in Treatment of Advanced Ovarian Cancer
    Lone, Abdul Rashid
    Ahmad, Mushtaq
    Kour, Sandeep
    Aziz, Sheikh Aejaz
    Banday, Manzoor A.
    Jeelani, Samoon
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2007, 28 (01) : 14 - 19
  • [50] Multidisciplinary procedures in the laparoscopic secondary cytoreductive surgery of advanced ovarian cancer
    Jiang, Qidi
    Chen, Mo
    Yuan, Lei
    Yao, Liangqing
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (12) : 1619 - 1620